Stellate Therapeutics Strengthens Senior Management Team

-Stellate Therapeutics Inc.( “Stellate”), a global biotechnology company developing disease-modifying therapies for neurological conditions based on molecules derived from the microbiome, is pleased to announce the appointments of Dr. David Immke, PhD, as Chief Scientific Officer, and Dr. Jonathan Weiss, PhD, MBA as Director, Business Development, effective immediately.
-Dr. Immke is a scientific leader who brings deep industry and neuroscience expertise to Stellate Therapeutics.

Read More »

OMNE POSSIBILE made it to “Top 15 Swiss Biotech Startups making a difference in Europe”.

-Founded: 2021 Location: Basel

-As a brand new synbio company, Omne Possibile develops new-to-nature nucleic acids (XNA), which are modified versions of the natural building blocks of DNA and RNA molecules. XNA can be customized for different industrial applications in the areas of healthcare, information technology, and smart materials. For example, to avoid the limitations of messenger RNA (mRNA), researchers could use mXNA instead of mRNA to develop modern vaccines, treat genetic diseases, or fight pests in agricultural settings.

-In May 2021, Omne Possibile announced an investment of an undisclosed amount by French company eureKARE, which recently launched with €49M ($60M) to finance next-generation biotech companies in Europe.

Read More »





Privacy & Cookies

France – Belgium – Luxembourg

Privacy & Cookies